 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Consequences of Serious Bleeding Complications from Warfarin
2 December 2003 | Volume 139 Issue 11 | Page I-22
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full report titled "Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism. A Meta-Analysis." It is in the 2 December 2003 issue of Annals of Internal Medicine (volume 139, pages 893-900). The authors are L.A. Linkins, P.T. Choi, and J.D. Douketis.
What is the problem and what is known about it so far?
Blood clots in the deep veins of the legs or pelvis are called deep venous thrombosis (DVT). These blood clots are dangerous because they can break free and travel to the lungs. This problem, called pulmonary embolism (clot in the lung), can be fatal. Doctors typically treat patients with DVT with blood-thinning drugs for 3 to 6 months. Some patients with high risks for repeated clots need even longer treatment. The blood-thinning drugs prevent the formation of new clots, reduce the risk that a clot will travel to the lungs, and prevent repeated clots. Doctors often use a powerful blood-thinning drug called warfarin to prevent repeated clots in patients with DVT. People taking this drug need frequent blood tests to make sure that the dose being given reduces the blood's tendency to clot, but not so much that bleeding occurs spontaneously. Even with careful monitoring, some patients who take warfarin have bleeding complications. The consequences of the bleeding complications aren't well known.
Why did the researchers do this particular study?
To describe the frequency and consequences of major bleeding in patients taking warfarin for DVT.
Who was studied?
10,757 patients from 33 studies.
How was the study done?
Rather than doing a new study, the researchers looked at previous studies that involved patients with DVT who were treated with warfarin-type drugs for at least 3 months. Patients in these studies weren't allowed to take other drugs, such as aspirin, that might affect blood clotting. Their doses of warfarin and clotting ability were monitored with particular blood tests (international normalized ratio targets of 2.0 to 3.0). The researchers summarized numbers of patients with major bleeding events that required hospitalization or a blood transfusion, numbers of patients with bleeding inside the skull (intracranial bleeding), and numbers of patients who died.
What did the researchers find?
Patients in the studies had 276 major bleeding events; 37 of these were fatal. Of 24 intracranial bleeding episodes, 11 were fatal. Risks for bleeding appeared highest within the first 3 months of starting warfarin. The summary estimated number of major bleeding events per 1000 patients taking warfarin for 1 year was 72. The summary estimated number of deaths from bleeding per 1000 patients taking warfarin for 1 year was 13.
What were the limitations of the study?
The reviewed studies used slightly different definitions of major bleeding events. Exact estimates of when bleeding occurred (for example, within 10 days of starting warfarin therapy) weren't possible because many studies did not report the time of each bleeding event.
What are the implications of the study?
Major bleeding events have serious consequences in people taking warfarin for DVT. About 1 in 8 people with major bleeding episodes die. Nearly 10% of major bleeding episodes are intracranial, and nearly 50% of these are fatal.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  A. Manganaro, G. Ando, D. Lembo, L. Sutera Sardo, and D. Buda A Retrospective Analysis of Hospitalized Patients With Documented Deep-Venous Thrombosis and Their Risk of Pulmonary Embolism Angiology, October 1, 2008; 59(5): 599 - 604. [Abstract] [PDF]
|
|
|
|
 |
|
 D. O. Claassen, N. Kazemi, A. Y. Zubkov, E. F. M. Wijdicks, and A. A. Rabinstein Restarting Anticoagulation Therapy After Warfarin-Associated Intracerebral Hemorrhage Arch Neurol, October 1, 2008; 65(10): 1313 - 1318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Rodger MD MSc, S. R. Kahn MD MSc, P. S. Wells MD MSc, D. A. Anderson MD, I. Chagnon MD, G. Le Gal MD PhD, S. Solymoss MD, M. Crowther MD, A. Perrier MD, R. White MD, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy Can. Med. Assoc. J., August 26, 2008; 179(5): 417 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Hozo and B. Djulbegovic When Is Diagnostic Testing Inappropriate or Irrational? Acceptable Regret Approach Med Decis Making, July 1, 2008; 28(4): 540 - 553. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Schulman, R. J. Beyth, C. Kearon, and M. N. Levine Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 257S - 298S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Douketis, P. B. Berger, A. S. Dunn, A. K. Jaffer, A. C. Spyropoulos, R. C. Becker, and J. Ansell The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 299S - 339S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kearon, S. R. Kahn, G. Agnelli, S. Goldhaber, G. E. Raskob, and A. J. Comerota Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 454S - 545S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Garcia Pharmacogenetic-guided and standard dosing did not differ for out-of-range INRs in patients initiating warfarin therapy Evid. Based Med., April 1, 2008; 13(2): 55 - 55. [Full Text] [PDF]
|
|
|
|
 |
|
 S. MADHWAL, A. M. LINCOFF, and D. D.K. ROLSTON Q: Should patients on long-term warfarin take aspirin for heart disease? Cleveland Clinic Journal of Medicine, March 1, 2008; 75(3): 206 - 208. [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Janjigian and B. E. Muhs Current Treatment of Acute Lower Extremity Deep Venous Thrombosis International Journal of Lower Extremity Wounds, March 1, 2008; 7(1): 15 - 20. [Abstract] [PDF]
|
|
|
|
 |
|
 J. D. Douketis, C. S. Gu, S. Schulman, A. Ghirarduzzi, V. Pengo, and P. Prandoni The Risk for Fatal Pulmonary Embolism after Discontinuing Anticoagulant Therapy for Venous Thromboembolism Ann Intern Med, December 4, 2007; 147(11): 766 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W Eikelboom, J. S Ginsberg, and J. Hirsh Anticoagulation for venous thromboembolism BMJ, March 31, 2007; 334(7595): 645 - 645. [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Henke, C. G. Pearce, D. M. Moaveni, A. J. Moore, E. M. Lynch, C. Longo, M. Varma, N. A. Dewyer, K. B. Deatrick, G. R. Upchurch Jr, et al. Targeted Deletion of CCR2 Impairs Deep Vein Thombosis Resolution in a Mouse Model. J. Immunol., September 1, 2006; 177(5): 3388 - 3397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Goodacre, M. Stevenson, A. Wailoo, F. Sampson, A.J. Sutton, and S. Thomas How should we diagnose suspected deep-vein thrombosis? QJM, June 1, 2006; 99(6): 377 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. van Walraven, A. Jennings, N. Oake, D. Fergusson, and A. J. Forster Effect of Study Setting on Anticoagulation Control: A Systematic Review and Metaregression Chest, May 1, 2006; 129(5): 1155 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Douketis, K. Arneklev, S. Z. Goldhaber, J. Spandorfer, F. Halperin, and J. Horrow Comparison of Bleeding in Patients With Nonvalvular Atrial Fibrillation Treated With Ximelagatran or Warfarin: Assessment of Incidence, Case-Fatality Rate, Time Course and Sites of Bleeding, and Risk Factors for Bleeding. Arch Intern Med, April 24, 2006; 166(8): 853 - 859. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-M. Roy, G. Meyer, B. Vielle, C. Le Gall, F. Verschuren, F. Carpentier, P. Leveau, A. Furber, and for the EMDEPU Study Group* Appropriateness of Diagnostic Management and Outcomes of Suspected Pulmonary Embolism Ann Intern Med, February 7, 2006; 144(3): 157 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. C. Sox Better Care for Patients with Suspected Pulmonary Embolism Ann Intern Med, February 7, 2006; 144(3): 210 - 212. [Full Text] [PDF]
|
|
|
|
|
|
G. V Robinson Pulmonary embolism in hospital practice BMJ, January 21, 2006; 332(7534): 156 - 160. [Full Text] [PDF]
|
|
|
|
 |
|
 B. F. Gage Pharmacogenetics-Based Coumarin Therapy Hematology, January 1, 2006; 2006(1): 467 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Krakow and T. L. Ortel Continuing Anticoagulation Following Venous Thromboembolism JAMA, December 28, 2005; 294(24): 3088 - 3088. [Full Text] [PDF]
|
|
|
|
|
|
D. Ost Continuing Anticoagulation Following Venous Thromboembolism--Reply JAMA, December 28, 2005; 294(24): 3088 - 3089. [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Wilke, R. L. Berg, H. J. Vidaillet, M. D. Caldwell, J. K. Burmester, and M. A. Hillman Impact of Age, CYP2C9 Genotype and Concomitant Medication on the Rate of Rise for Prothrombin Time During the First 30 Days of Warfarin Therapy Clin. Med. Res., November 1, 2005; 3(4): 207 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Claes, F. Buntinx, J. Vijgen, J. Arnout, J. Vermylen, S. Fieuws, and H. Van Loon The Belgian Improvement Study on Oral Anticoagulation Therapy: a randomized clinical trial Eur. Heart J., October 2, 2005; 26(20): 2159 - 2165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Aujesky, K. J. Smith, J. Cornuz, and M. S. Roberts Cost-Effectiveness of Low-Molecular-Weight Heparin for Treatment of Pulmonary Embolism Chest, September 1, 2005; 128(3): 1601 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Hart, S. B. Tonarelli, and L. A. Pearce Avoiding Central Nervous System Bleeding During Antithrombotic Therapy: Recent Data and Ideas Stroke, July 1, 2005; 36(7): 1588 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Spinler, P. Dobesh, C. Macie, and J. Douketis Dose Capping Enoxaparin Is Unjustified and Denies Patients With Acute Coronary Syndromes a Potentially Effective Treatment Chest, June 1, 2005; 127(6): 2288 - 2290. [Full Text] [PDF]
|
|
|
|
|
|
P. S. Wells, D. R. Anderson, M. A. Rodger, M. A. Forgie, P. Florack, D. Touchie, B. Morrow, L. Gray, K. O'Rourke, G. Wells, et al. A Randomized Trial Comparing 2 Low-Molecular-Weight Heparins for the Outpatient Treatment of Deep Vein Thrombosis and Pulmonary Embolism Arch Intern Med, April 11, 2005; 165(7): 733 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Zacharski, P. Prandoni, and M. Monreal Warfarin Versus Low-Molecular-Weight Heparin Therapy in Cancer Patients Oncologist, January 1, 2005; 10(1): 72 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. W. Rathbun, T. L. Whitsett, and G. E. Raskob Negative D-dimer Result To Exclude Recurrent Deep Venous Thrombosis: A Management Trial Ann Intern Med, December 7, 2004; 141(11): 839 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Wakefield Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran Perspectives in Vascular Surgery and Endovascular Therapy, December 1, 2004; 16(4): 333 - 334. [Abstract] [PDF]
|
|
|
|
 |
|
 C. D Eckhoff, R. J DiDomenico, and N. L Shapiro Initiating Warfarin Therapy: 5 mg versus 10 mg Ann. Pharmacother., December 1, 2004; 38(12): 2115 - 2121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Smythe, W. E. Dager, and N. M. Patel Managing Complications of Anticoagulant Therapy Journal of Pharmacy Practice, October 1, 2004; 17(5): 327 - 346. [Abstract] [PDF]
|
|
|
|
|
|
M. N. Levine, G. Raskob, R. J. Beyth, C. Kearon, and S. Schulman Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 287S - 310S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kearon Long-Term Management of Patients After Venous Thromboembolism Circulation, August 31, 2004; 110(9_suppl_1): I-10 - I-18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Bates and J. S. Ginsberg Treatment of Deep-Vein Thrombosis N. Engl. J. Med., July 15, 2004; 351(3): 268 - 277. [Full Text] [PDF]
|
|
|
|
|
|
C. G. Elliott and L. J. Rubin Mars or Venus -- Is Sex a Risk Factor for Recurrent Venous Thromboembolism? N. Engl. J. Med., June 17, 2004; 350(25): 2614 - 2616. [Full Text] [PDF]
|
|
|
|
 |
|
 Learning More About Anticoagulant-Related Bleeding Risk in VTE Patients Journal Watch Cardiology, January 30, 2004; 2004(130): 3 - 3. [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
